<DOC>
	<DOCNO>NCT00518739</DOCNO>
	<brief_summary>This first-in-human trial establish safety , tolerability , Recommended Phase II Dose ( RP2D ) , pharmacodynamic , clinical activity MK2461 .</brief_summary>
	<brief_title>MK2461 Patients With Advanced Cancer ( 2461-001 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must least 18 year age , adequate organ function , ECOG performance &lt; 2 Patients must willing undergo prestudy post dose tumor biopsy tumor accessible biopsy ( waive Part A ) No chemotherapy , radiotherapy , biological therapy 4 week study participation Patients must primary central nervous system tumor Patient prescription nonprescription drug product know metabolized CYP3A4 discontinue prior Day 1 dose withheld throughout study 2 week last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>